IL17A and psoriatic arthritis: Fully human monoclonal antibody ixekizumab (Taltz) by Eli Lilly and Co., blocking IL-17A-mediated signaling, is approved for treatment of moderate-to-severe forms of plaque psoriasis and psoriatic arthritis [26].